Efficacy and Safety of Upadacitinib for Refractory Inflammatory Bowel Disease: A Multicenter Real-World Observational Study - PubMed
6 hours ago
- #Refractory IBD
- #Upadacitinib
- #Real-World Study
- The study evaluated upadacitinib in 80 Asian patients with refractory inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).
- During induction, clinical and endoscopic remission/response rates were significant, e.g., 59.6% steroid-free clinical remission in CD and 67.9% in UC.
- At 12 months, maintenance outcomes improved further, with 78.8% steroid-free clinical remission in CD and 85.7% in UC.
- Adverse events occurred in 23.1% of CD and 14.3% of UC patients, with acne being most common (8.75%); discontinuation rates were 7.1% (CD) and 21.5% (UC).
- The conclusion highlights upadacitinib's robust real-world efficacy and acceptable safety profile in this population.